- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Canadian vendor lands contracts
Cedara Software (Mississauga, Ontario) has agreed to supply Instrumentarium Imaging (Helsinki, Finland) with a customized version of its Cedara I-Acquire/MG digital acquisition software. The software will be used in Instrumentarium's Diamond full-field
Cedara Software (Mississauga, Ontario) has agreed to supply Instrumentarium Imaging (Helsinki, Finland) with a customized version of its Cedara I-Acquire/MG digital acquisition software. The software will be used in Instrumentarium's Diamond full-field digital mammography system. According to the Dec. 19 announcement, I-Acquire will integrate the flat-panel digital detector, controller, and x-ray generator. I-Acquire will also provide automated workflow, image display manipulation, DICOM communication, and information system integration. Its open architecture will allow the future integration of clinical applications and advanced image processing algorithms, according to Cedara.
The company's I-Acquire software will be integrated into a digital radiography product being manufactured in China. I-Acquire will be supplied to Beijing WanDong Medical Equipment, one of China's largest x-ray equipment manufacturers, as part of a deal announced Dec. 13. The transaction with WanDong also includes Cedara's I-SoftView diagnostic workstation. Cedara designed the software to interface with multiple x-ray acquisition devices, including digital flat-panel detectors as well as computed radiography scanners and readers. I-Acquire features multiple control support, patient demographics, procedure input, intuitive image manipulation tools, and image enhancement algorithms that automatically optimize clinical images, quickening patient throughput.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
